Multiple Organ Failure
52
2
4
22
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.9%
1 terminated out of 52 trials
95.7%
+9.1% vs benchmark
19%
10 trials in Phase 3/4
14%
3 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (52)
Adding a Gastrointestinal Subscore to SOFA2 for Mortality Risk Assessment in the ICU: The SOFA2-GIS Study
TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure
Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF
Actualities in Procedural Sedation: Remimazolam
Dalargin for Prevention of Organ Disfunction in High-Risk Abdominal Surgery
Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study
Facilitating Communication Study
Incidence of Acute Kidney Injury and Risk Factors in Newborns With Congenital Diaphragmatic Hernia
Early Metabolic Resuscitation for Septic Shock
Polish Nationwide Register of Hospitalized Patients in Cardiac Intensive Care Units
Burden, Mortality and Supply Costs in Intensive Care Unit Patients
Severe Sepsis/Septic Shock on Admission to the General Surgical ICU
Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients
Observational Trial on Cytokine Adsorption in Sepsis
Evaluation of the Effectiveness of Extracorporeal Methods for Removing Mediators of Systemic Inflammation
Innovative Technologies for the Treatment of Pulmonary and Heart Failure
Clinical Use of Stem Cells for the Treatment of Covid-19
Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients
Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System
Feasibility Study of MicroKine Dx System in Critically-ill Pediatric Patients.